Clinical trials: Pancreas Tumor
Pancreatic Ductal Adenocarcinoma
Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer
This clinical trial investigates the nutrients pancreatic cancers depend on in which to survive and the processes these tumors use (metabolism) to obtain these nutrients.
- Trial name
- NCT05296421
- Testing
- Biopsy, Therapeutic Conventional Surgery, Uniformly-labeled [13C]glucose
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Rutgers, The State University of New Jersey
Well Differentiated Pancreatic Endocrine Tumor
Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs
Abnormal PI3K-Akt-mTOR (mammalian target of rapamycin) pathway signaling and autocrine activation of the mTOR pathway, mediated through insulin-like growth factor 1 (IGF1), has been implicated in the proliferation of pNET …
- Trial name
- MetNET1 (NCT02294006)
- Testing
- Everolimus plus Octreotide LAR plus Metformin
- Where
- Italy
- Volunteers
- 26 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Pancreas Cancer
Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer
Patients are being asked to participate in this study who have locally advanced or metastatic pancreatic cancer (cancer of the pancreas that has spread to another part of the body) that has gotten worse after first-line…
- Trial name
- NCT00881621
- Testing
- Lapatinib and Capecitabine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Georgetown University
PDAC - Pancreatic Ductal Adenocarcinoma
Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resectability
The main objective is the evaluation of the prognostic value of ctDNA (circulating tumor DNA) as a marker of surgical futility in patients with operable PDAC.
- Trial name
- CASPER (NCT05853198)
- Testing
- ctDNA analysis
- Where
- Italy
- Volunteers
- 165 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Pancreatic Cancer
Phase I-II to Evaluate Efficacy/Safety of Sorafenib+Gemcitabine+Radiotherapy in Locally Advanced Pancreatic Carcinoma
Phase I: Safety profile and to determine maximum tolerated dose (MTD) / Recommended Dose (DR) of Sorafenib in combination with Gemcitabine and Radiotherapy Phase II: Activity profile evaluating Progression-free rates (PFR) at 6…
- Trial name
- NCT00789763
- Testing
- Gemcitabine, Radiotherapy, Sorafenib
- Where
- 4 sites in Spain
- Volunteers
- 12 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Colorectal Cancer, Pancreatic Cancer
Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Colorectal Cancer or Pancreatic Cancer
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00004087
- Testing
- filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Gastric Cancer, Colorectal Cancer
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
This is a Phase 2 study to evaluate the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in patients with locally advanced, recurrent, or…
- Conditions
- Gastric Cancer, Colorectal Cancer, Pancreatic Cancer, Sarcoma
- Trial name
- NCT03935893
- Testing
- Tumor Infiltrating Lymphocytes (TIL), Fludarabine + Cyclophosphamide combination
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Udai Kammula
Endoscopic Ultrasound-Guided Radiofrequency Ablation, Pancreatic Neuroendocrine Tumors (pNET)
Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Cystic Neoplasms and Pancreatic Neuroendocrine Tumors
The primary aim of this study is to evaluate the technical feasibility and effectiveness of endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) in the treatment of pancreatic cystic neoplasms (PCNs) and pancreatic…
- Conditions
- Endoscopic Ultrasound-Guided Radiofrequency Ablation, Pancreatic Neuroendocrine Tumors (pNET), Pancreatic Cystic Neoplasms
- Trial name
- NCT07536087
- Testing
- Endoscopic ultrasound-guided radiofrequency ablation for pancreatic cystic lesions, Endoscopic ultrasound-guided radiofrequency ablation of pancreatic solid lesions
- Where
- Czechia
- Volunteers
- 50 people
- Sponsor
- Institute for Clinical and Experimental Medicine
Pancreatoduodenectomy, Periampullary Carcinoma
Application of "Heidelberg Triangle" Dissection in Pancreatoduodenectomy and Distal Pancreatectomy
Aim of the study : To evaluate the effect and safety of "Heidelberg Triangle" dissection (TRIANGLE operation) combined with Pancreatoduodenectomy or Distal Pancreatectomy on the prognosis of pancreatic cancer and periampullary…
- Conditions
- Pancreatoduodenectomy, Periampullary Carcinoma, Pancreatic Cancer
- Trial name
- NCT05703581
- Testing
- TRIANGLE operation
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fudan University
Chronic Pancreatitis, Pancreatic Cancer
A Prospective Study of EUS Guided Celiac Block
The purpose of this prospective study is to measure the clinical effectiveness of EUS-guided CB in subjects, 50 who have chronic pancreatitis and 50 who have pancreatic cancer, that are already undergoing celiac block for…
- Trial name
- NCT00583271
- Testing
- triamcinolone, 98% dehydrated alcohol
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- Indiana University
Pancreatic Cancer, Liver Metastasis
A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009）
This is a a single-arm, prospective study of Camrelizumab combined with ablation and chemotherapy for patients with Pancreatic cancer liver metastasis.
- Trial name
- NCT04420130
- Testing
- Camrelizumab, Chemotherapy, Ablation
- Sponsor
- Yanqiao Zhang
Metastatic Pancreatic Cancer
Direct Tumor Injection KLH-Pulsed Dendritic Cells in Unresectable Pancreatic Cancer
This research study uses radiation or a gene therapy agent, TNFerade in addition to a dendritic cell vaccine in patients with locally advanced or low volume metastatic pancreatic cancer.
- Trial name
- NCT00868114
- Testing
- KLH-pulsed autologous dendritic cell vaccine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Leo W. Jenkins Cancer Center
Pancreatic Cancer
Safety and Efficacy Study of P276-00 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer
The purpose of this study is to identify a dose of P276-00 that can be safely administered along with Gemcitabine and to examine safety and efficacy of the combination in treatment of advanced pancreatic cancer.
- Trial name
- SAVIOR (NCT00898287)
- Testing
- P276-00, Gemcitabine
- Where
- 7 sites in India
- Volunteers
- 23 people
- Sponsor
- Piramal Enterprises Limited
Pancreatic Adenocarcinoma Non-resectable
PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer
This is a single arm phase II trial assessing the potential activity of combination PEGPH20 plus Gemcitabine with radiotherapy in ten patients with localized, unresectable pancreatic adenocarcinoma.
- Trial name
- HALO-IST (NCT02910882)
- Testing
- PEGylated Recombinant Human Hyaluronidase (PEGPH20), Gemcitabine, Radiation
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Scripps Health
Pancreatic Cancer
Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy
This protocol (NLG0705) provides a mechanism for the 15-year follow-up period that the FDA requires for all participants in gene transfer protocols and assures that adequate follow-up can be maintained for subjects who have…
- Trial name
- NCT03165188
- Where
- 15 sites in United States
- Volunteers
- 29 people
- Sponsor
- NewLink Genetics Corporation
Pancreatic Cancer, Common Bile Duct Diseases
A Prospective Study on the Safety and Efficacy of Robot-assisted Pancreaticoduodenectomy
Further studies are needed to investigate the prognosis and perioperative safety of patients undergoing robotic-assisted pancreaticoduodenectomy.
- Conditions
- Pancreatic Cancer, Common Bile Duct Diseases, Periampullary Carcinoma
- Trial name
- NCT05755594
- Testing
- Robot-assisted Pancreaticoduodenectomy
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital of University of South China
Pancreatic Cancer
Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas
The primary goal of the research study is to determine whether treating pancreatic cancer patients with hydroxychloroquine in combination with gemcitabine before surgery is safe.
- Trial name
- NCT01128296
- Testing
- Hydroxychloroquine, Gemcitabine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Amer Zureikat
Adenocarcinoma of the Pancreas, Pancreas Cancer
Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B
Standard treatment for newly diagnosed operable pancreatic cancer usually involves undergoing surgery first and then receiving chemotherapy with or without radiation therapy.
- Trial name
- NCT03778879
- Testing
- CCX872-B
- Where
- United States
- Sponsor
- Alan Katz
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer
A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation
This is a phase II, single center, open label, multi-cohort platform study to identify a signature in tumor tissues, blood or stool that might help identify participants who are more likely to experience tumor shrinkage or side…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- DOME (NCT04262388)
- Testing
- Durvalumab, Oleclumab
- Where
- Canada
- Sponsor
- University Health Network, Toronto
Pancreatic Cancer Non-resectable
Open Label Immunotherapy Trial of Inoperable Pancreatic Cancer
Pancreatic cancer (PDA) is the most lethal form of cancer, and the fourth-leading cause of cancer-related death in the United States, with a survival rate of less than 7%.There are currently no treatments found to be effective…
- Trial name
- V3-P (NCT03165591)
- Testing
- V3-P
- Where
- 2 sites in Mongolia
- Volunteers
- 30 people
- Sponsor
- Immunitor LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.